BARD1 teams up with Institute for Respiratory Health to evaluate its cancer vaccine
BARD1 Life Sciences (ASX:BD1) announced on Tuesday that it had entered into a collaboration agreement with the Institute for Respiratory Health (IRH) in order to evaluate the company’s cancer vaccine for the prevention and/or treatment of cancer in animal models.
By way of background, BARD Life Sciences is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. The group’s lead product, the BARD1 lung cancer test is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm.
The company’s pipeline also includes the BARD1 Ovarian Cancer Test, which is in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research stage for multiple cancers.
The collaboration agreement is an important development given that the Institute for Respiratory Health is supported by world-class researchers and dedicated clinicians who focus on investigating, diagnosing, treating and preventing respiratory conditions.
However, it should be noted here that this company represents a speculative investment and those considering this stock for their portfolio should seek professional financial advice before making a decision.
The project will evaluate various BARD1 formulations across several fully characterised tumour cell lines to determine their effectiveness in preventing tumour growth or reducing tumour size in two industry-accepted tumour models in mice.
It will also determine the optimal dose and timing for vaccination, as well as other secondary outcomes.
In fleshing out the key benefits of this collaboration agreement, BD1 Chief Executive, Doctor Learnne Hinch said, “We have already demonstrated the utility of this technology in the diagnostic area, but therapeutic applications offer a large upside potential and, if the animal studies demonstrate effectiveness, this collaboration will enable us to advance our therapeutic program towards preclinical development”.
Professor Geoff Laurent, director of the IRH provided a strong endorsement of BD1’s progress, saying, “We believes the BARD1 Technology has much to offer in the field of therapeutic vaccines for lung cancer, and this is precisely the kind of mutually beneficial research collaboration that if successful will expand the therapeutic options for cancer patients”.
BCC Research valued the global cancer vaccine market at US$3.5 billion in 2016.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.